Buck AK - Search Results

1

CXCR4-targeted theranostics in oncology.

Buck AK, Serfling SE, Lindner T, Hänscheid H, Schirbel A, Hahner S, Fassnacht M, Einsele H, Werner RA. Buck AK, et al. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4133-4144. doi: 10.1007/s00259-022-05849-y. Epub 2022 Jun 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 35674738 Free PMC article. Review.

2

Facing the nuclear threat: thyroid blocking revisited.

Hänscheid H, Reiners C, Goulko G, Luster M, Schneider-Ludorff M, Buck AK, Lassmann M. Hänscheid H, et al. Among authors: buck ak. J Clin Endocrinol Metab. 2011 Nov;96(11):3511-6. doi: 10.1210/jc.2011-1539. Epub 2011 Aug 24. J Clin Endocrinol Metab. 2011. PMID: 21865356

3

[131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma.

Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, Buck AK, Reiners C, Allolio B, Schirbel A. Hahner S, et al. Among authors: buck ak. J Clin Endocrinol Metab. 2012 Mar;97(3):914-22. doi: 10.1210/jc.2011-2765. Epub 2011 Dec 14. J Clin Endocrinol Metab. 2012. PMID: 22170726

4

PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.

Hänscheid H, Sweeney RA, Flentje M, Buck AK, Löhr M, Samnick S, Kreissl M, Verburg FA. Hänscheid H, et al. Among authors: buck ak. Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1284-8. doi: 10.1007/s00259-012-2124-x. Epub 2012 Apr 20. Eur J Nucl Med Mol Imaging. 2012. PMID: 22526964

5

Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.

Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M, Reiners C, Samnick SS, Buck AK, Flentje M, Sweeney RA. Kreissl MC, et al. Among authors: buck ak. Radiat Oncol. 2012 Jun 21;7:99. doi: 10.1186/1748-717X-7-99. Radiat Oncol. 2012. PMID: 22720902 Free PMC article. Clinical Trial.

6

Improved follow-up of patients with differentiated thyroid carcinoma. The quantitative detection limit of 131I uptake in diagnostic scans.

Dießl S, Verburg F, Biko J, Schryen B, Reiners C, Buck A, Hänscheid H. Dießl S, et al. Nuklearmedizin. 2013;52(3):81-7. doi: 10.3413/Nukmed-0525-12-08. Epub 2013 Feb 13. Nuklearmedizin. 2013. PMID: 23403717 Clinical Trial.

7

Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT.

Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, Verburg FA, Knoedler P, Lang K, Reiners C, Buck AK, Allolio B, Schirbel A. Hahner S, et al. Among authors: buck ak. J Clin Endocrinol Metab. 2013 Apr;98(4):1508-18. doi: 10.1210/jc.2012-3045. Epub 2013 Feb 20. J Clin Endocrinol Metab. 2013. PMID: 23426614

8

[¹²³I]Iodometomidate imaging in adrenocortical carcinoma.

Kreissl MC, Schirbel A, Fassnacht M, Haenscheid H, Verburg FA, Bock S, Saeger W, Knoedler P, Reiners C, Buck AK, Allolio B, Hahner S. Kreissl MC, et al. Among authors: buck ak. J Clin Endocrinol Metab. 2013 Jul;98(7):2755-64. doi: 10.1210/jc.2012-3261. Epub 2013 Apr 22. J Clin Endocrinol Metab. 2013. PMID: 23609836

9

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging.

Buder K, Lapa C, Kreissl MC, Schirbel A, Herrmann K, Schnack A, Bröcker EB, Goebeler M, Buck AK, Becker JC. Buder K, et al. Among authors: buck ak. BMC Cancer. 2014 Apr 17;14:268. doi: 10.1186/1471-2407-14-268. BMC Cancer. 2014. PMID: 24742330 Free PMC article.

10

The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma.

Hänscheid H, Lassmann M, Buck AK, Reiners C, Verburg FA. Hänscheid H, et al. Among authors: buck ak. Phys Med Biol. 2014 May 21;59(10):2353-68. doi: 10.1088/0031-9155/59/10/2353. Epub 2014 Apr 17. Phys Med Biol. 2014. PMID: 24743333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

346 results

Search Page